

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fernandez-Salas et al.
Serial Number: 10/759,746
Customer No.: 051957
Filed: January 16, 2004

Examiner: Chang Yu Wang
Art Unit: 1649
Confirmation No.: 6885

For: METHODS OF IDENTIFYING
COMPOUNDS THAT ALTER TOXIN
PERSISTENCE AND/OR PROTEASE
ACTIVITY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant's provide with regard to the patent application a listing of documents s on the attached Information Disclosure Citation (Form PTO-1449) which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56.

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists.

Each item of information contained in this Supplemental Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

Respectfully submitted,

/Dean G. Stathakis/

Dean G. Stathakis, Ph.D.
Registration Number 54,465

Please direct all inquiries and correspondence to:

Dean G. Stathakis
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246-6521
Fax: 714.246-4249